Results 91 to 100 of about 510,668 (221)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

The state of cardio-oncology in Oman: awareness, practices, and training needs among healthcare providers: a survey-based study

Cardio-Oncology
Background Cardio-oncology has emerged as a multidisciplinary subspecialty to address the growing burden of cancer therapy–related cardiovascular toxicity and its impact on morbidity and mortality.
Ahmed Basuoni, Bushra Salman, Khalid Al-Baimani, Suhaila Al Farsi, Waleed Dawelbeit, Mohamed Barakat Al Riyami, Marwa Ahmed Makhlouf, Issa Al Qarshoubi, Adil Barakat Al Riyami, Mohamed Najeeb Al Rawahi   +9 more
doaj   +1 more source

Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology

Cardio-oncology was established with the aim of defining primary and secondary prevention approaches through surveillance and the use of tools to stratify and diminish the cardiovascular risk to cancer patients.
Tamburrini, Giulia, Maggio, Luca, Camilli, Massimiliano, Torre, Ilaria, Viscovo, Marcello, Lombardo, Antonella, Rocca, Bianca   +6 more
core   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Cardio-oncology: concepts and practice [PDF]

, 2016
Substantial progress in cancer therapy increasingly allows higher cure rates, and even advanced disease can be stabilized, allowing improved survival with quality of life for months to years, meaning comorbid diseases are a growing determinant of outcome.
Cubbon, RM, Cubbon, Richard M., Lyon, AR, Alexander R. Lyon, Richard M. Cubbon, Lyon, Alexander R.   +5 more
core   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Challenges and opportunities for improving cardiovascular health in women with breast cancer: a review

Cardio-Oncology
Background Breast cancer survivors are at a high risk of developing cardiovascular disease (CVD) owing to cancer treatment. Breast cancer and CVD share common risk factors, necessitating CVD risk assessment along with cancer screening.
Sana Ali, Kerri A. Mullen
doaj   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann, Zsanett Papdi, Nils J. Strauch, Daniel Finke, Marc‐Steffen Raab, Antje Blank, Norbert Frey, Lorenz H. Lehmann   +7 more
wiley   +1 more source

Integrating Cardio-Oncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective

Over 18 million people worldwide were diagnosed with cancer in 2020, including over 150,000 people in Australia. Although improved early detection and treatment have increased the survival rates, cardiotoxic treatment and inadequate management of ...
Koczwara, B., Sverdlov, A.L., Garvey, G., Singleton, A.C., Redfern, J., Williams, T.D., La Gerche, A., Diaz, A., Doyle, K., Conyers, R., Hunt, L., Figtree, G.A., Ngo, D.T.M., Cehic, D.A., Playford, D., Nicholls, S.J., Negishi, K., Australian Cardiovascular Alliance Cardio-Oncology Working Group,   +17 more
core   +1 more source